🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against superbug strains of the bacteria, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are on the rise worldwide, with figures suggesting in excess of 82 million infections annually. Notably increased rates are reported in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Secure Clearance

Zoliflodacin, also known as a brand name, was approved by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Data and Worldwide Availability

According to findings published in a major medical journal, the new drug cured more than 90% of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which involves an injection and a pill. The trial included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have shared hope. Access to a single-dose, oral treatment such as this is hailed as a "revolutionary step" for gonorrhoea control. This is deemed vital to lessen the impact of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.